The influence of antidiabetic medications on the development and progression of prostate cancer

Anna Hitron, Val Adams, Jeff Talbert, Doug Steinke

Research output: Contribution to journalShort surveypeer-review

34 Scopus citations

Abstract

Background: The development of prostate tumors has been linked to co-morbid diabetes mellitus (DM) in several studies, potentially through the stimulation of insulin-like growth factor receptor (IGFR). This study evaluates the effect of anti-diabetic medication use on the development of high grade tumors and time to tumor progression compared to non-diabetics. Methods: This retrospective, nested case control study identified patients with prostate cancer (PCa) from the Kentucky Medicaid Database. Cases were diagnosed with PCa and DM and using at least one of the following antidiabetic medications; sulfonylureas, insulin, metformin or TZDs. Cases were further stratified on their insulin exposure resulting from therapy. Controls were those with PCa without DM or any anti-diabetic medications. Results: The use of metformin or TZDs trended toward decreased odds of high-grade tumors and decreased risk of progression, while sulfonylureas and high-dose insulin tended toward an increased odds of high-grade tumors and increase the risk of progression compared to non-diabetics. Conclusions: Future studies should be conducted to further evaluate the effects of anti-diabetic medications on tumor grade and time to prostate cancer progression.

Original languageEnglish
Pages (from-to)e243-e250
JournalCancer Epidemiology
Volume36
Issue number4
DOIs
StatePublished - Aug 2012

Bibliographical note

Funding Information:
The work described above was supported by a grant from the American Cancer Society .

Keywords

  • Diabetes
  • IGFR
  • Insulin
  • Prostate cancer
  • Prostate tumor

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The influence of antidiabetic medications on the development and progression of prostate cancer'. Together they form a unique fingerprint.

Cite this